CFDE Data Portal | Search LOC124902694

	Label	Description
	LOC124902694 Gene (Entity type)	ENSG00000255320 - uncharacterized LOC124902694
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 5 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE153354 TCF19 knockout CAL-27 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE218060 decitabine T cell 2 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199862 Chk1 inhibition 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 3 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE218060 decitabine T cell 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC124902694

ENSG00000255320 - uncharacterized LOC124902694

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE233679 nicotinamide 5 v 13 human up

A Gene Set from LINCS

GSE153354 TCF19 knockout CAL-27 0 v 1 human dn

A Gene Set from LINCS

GSE218060 decitabine T cell 2 v 6 human dn

A Gene Set from LINCS

GSE199862 Chk1 inhibition 3 v 2 human dn

A Gene Set from LINCS

GSE216043 cisplatin 3 v 4 human dn

A Gene Set from LINCS

GSE195568 palbociclib 6 v 7 human up

A Gene Set from LINCS

GSE128076 doxycycline HEK293 2 v 0 human up

A Gene Set from LINCS

GSE218060 decitabine T cell 7 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.